Clinical trials: Gastric Cancer
Cancer
Multiple Ascending Dose of BMS-911543
The purpose of this first in human study is to determine if BMS-911543 is safe and tolerable in subjects with symptomatic intermediate-1, intermediate-2 or high risk myelofibrosis to permit clinical testing at the Maximum…
- Trial name
- NCT01236352
- Testing
- BMS-911543
- Where
- 5 sites in United States, Australia
- Volunteers
- 98 people
- Sponsor
- Bristol-Myers Squibb
Gastric Ulcer (GU), Duodenal Ulcer (DU)
A Phase I/III Study of D961H 10 mg and 20 mg in Japanese Paediatric Patients With Gastrointestinal Acid Related Diseases
The objective of this study is to assess the safety, pharmacokinetics, pharmacodynamics and efficacy of repeated once daily oral administration of D961H 10 mg and D961H 20 mg in Japanese paediatric patients aged 1 to 14 years old…
- Conditions
- Gastric Ulcer (GU), Duodenal Ulcer (DU), Anastomotic Ulcer (AU), Non-erosive Reflux Esophagitis Disease (NERD)
- Trial name
- NCT02153398
- Testing
- D961H sachet 10 mg, D961H capsule 10mg, D961H capsule 20 mg
- Where
- 15 sites in Japan
- Volunteers
- 55 people
- Sponsor
- AstraZeneca
Colorectal Neuroendocrine Tumor G1, Gastric Neuroendocrine Tumor G1
Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
This randomized phase III trial studies octreotide acetate and recombinant interferon alfa-2b to see how well it works compared to octreotide acetate and bevacizumab in treating patients with high-risk neuroendocrine tumors that…
- Conditions
- Colorectal Neuroendocrine Tumor G1, Gastric Neuroendocrine Tumor G1, Neuroendocrine Neoplasm, Neuroendocrine Tumor
- Trial name
- NCT00569127
- Testing
- Bevacizumab, Laboratory Biomarker Analysis, Octreotide Acetate
- Where
- 493 sites in United States
- Volunteers
- 427 people
- Sponsor
- National Cancer Institute (NCI)
Glioblastoma Multiforme, Anaplastic Astrocytoma
INCB7839 in Treating Children With Recurrent/Progressive High-Grade Gliomas
This is a multicenter phase 1 trial of INCB7839 for children with recurrent or progressive high-grade gliomas, including, but not limited to, diffuse intrinsic pontine glioma (DIPG) and other diffuse midline gliomas (DMGs), after…
- Conditions
- Glioblastoma Multiforme, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, DIPG
- Trial name
- NCT04295759
- Testing
- INCB7839
- Where
- 11 sites in United States
- Volunteers
- 13 people
- Sponsor
- Pediatric Brain Tumor Consortium
Gastroenteropancreatic Neuroendocrine Tumors, Pheochromocytoma
Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs
This is a multicenter, open-label, single-arm study to evaluate the safety and dosimetry of Lutathera in adolescent patients 12 to <18 years old with somatostatin receptor positive GEP-NETs and PPGLs.
- Conditions
- Gastroenteropancreatic Neuroendocrine Tumors, Pheochromocytoma, Paraganglioma
- Trial name
- NETTER-P (NCT04711135)
- Testing
- Lutetium [177Lu] oxodotreotide/dotatate
- Where
- 7 sites in United States, France and 3 more
- Volunteers
- 11 people
- Sponsor
- Advanced Accelerator Applications
Gastric Cancer, Gastroesophageal Junction Cancer
Human Epidermal Growth Factor Receptor 2 (HER-2) Status in Gastric and Gastro-Esophageal Junction (GEJ) Carcinoma
The primary objective is to evaluate the concordance between human epidermal growth factor receptor 2 (HER2) status determined by the participating laboratory and by the centralized laboratory.
- Trial name
- NCT02731313
- Testing
- Trastuzumab
- Where
- 19 sites in France
- Volunteers
- 420 people
- Sponsor
- Hoffmann-La Roche
Pain, Neuropathic, Epilepsy
Cancer in Patients With Gabapentin (GPRD)
High doses of gabapentin are associated with pancreatic acinar cell tumors in rats, but there has been no post marketing pancreatic carcinogenicity signal with gabapentin as reported by spontaneous reports in AERS or in the…
- Conditions
- Pain, Neuropathic, Epilepsy, Renal Pelvis Cancer, Pancreatic Cancer
- Trial name
- NCT01236053
- Testing
- Gabapentin prescriptions
- Volunteers
- 2,323,608 people
- Sponsor
- GlaxoSmithKline
Gastric Cancer
Safety and Efficacy of Trastuzumab BS
To confirm the safety and efficacy of this drug under the actual use
- Trial name
- NCT04181333
- Testing
- TRASTUZUMAB BS
- Where
- Japan
- Volunteers
- 8 people
- Sponsor
- Pfizer